T~reg~ Suppress Pro-Tumoral Inflammation or Anti-Tumor Response {#S1}
===============================================================

Introduction {#S1-1}
------------

Tumor onset is a very complex process, in which cells of both innate and adaptive immune system play crucial roles in inhibiting or fostering tumor development. The awareness that the immune system could act as an extrinsic tumor suppressor or as a tumor-sculpting player resulted in the cancer immunoediting theory, which described the interaction between tumor and host as consisting of three different phases: elimination, equilibrium, and escape ([@B1]). During the last phase of this process, transformed cells acquire the ability to subvert the control exerted by immune cells thus originating the clinically evident pathology. The escape is due to different mechanisms, including reduced immunogenicity (low expression level of MHC class I and loss of antigen expression), acquired resistance to the cytotoxic functions of immune cells, and accumulation in the tumor microenvironment of immunosuppressive mediators, like regulatory T cells (T~reg~) ([@B1]). The first marker to be identified as distinguishing T~reg~ from the other CD4^+^ T lymphocytes was CD25 ([@B2]) and depletion of CD25-positive cells unveiled anti-tumor immunity in experimental models ([@B3]). Few years later, the transcription factor Forkhead Box P3 (Foxp3) was indicated as the master regulator of T~reg~ ([@B4], [@B5]). In support of the crucial roles played by Foxp3 in T~reg~ fate determination and immune homeostasis, Foxp3 mutations have been recognized as responsible for human Immune Dysfunction, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome ([@B6], [@B7]), and for the phenotype of scurfy mutant mice ([@B8]), both characterized by fatal autoimmune lymphoproliferation linked to severe defects in T~reg~ development/functions. However, very recent data have demonstrated that the complete development of the T~reg~ lineage requires the concomitant, Foxp3-independent, establishment of a T~reg~-specific pattern of DNA hypomethylation ([@B9]).

According to recently proposed recommendations ([@B10]), T~reg~ are classified into two principal subsets based on their developmental origin: thymus-derived T~reg~ (tT~reg~) develop in the thymus, while peripherally induced T~reg~ (pT~reg~) develop *in vivo* in the periphery from conventional T cells (T~conv~), through a process called "conversion" ([@B11]). T~reg~ can also be induced *in vitro* (and are called iT~reg~) under TGF-β and/or retinoic acid exposure, but their complete commitment into fully differentiated T~reg~ is still under debate ([@B12]). In physiological conditions, the pool of T~reg~, encompassing both tT~reg~ and pT~reg~, which represents about the 5--10% of the circulating CD4^+^ T lymphocytes, assures peripheral self-tolerance and prevents exacerbated immune responses ([@B7], [@B8]). A huge amount of data now demonstrates that tumor onset and progression perturb T~reg~ homeostasis and lead to increased T~reg~/T~conv~ and T~reg~/CD8 ratios both in peripheral blood and in the tumor microenvironment ([@B13]). The accumulation of T~reg~ at tumor sites may be due to the concomitant or the preferential occurrence of distinct events, such as the recruitment of T~reg~ from periphery, the proliferation of pre-existing T~reg~ in the tumor microenvironment, and the *de novo* conversion of tumor-infiltrating CD4^+^ lymphocytes (TIL) into pT~reg~ ([@B14], [@B15]). Despite controversy existing over the dominant suppression mechanism, and despite the incomplete understanding of the biological meaning of T~reg~ accumulation in cancer, it is well accepted that T~reg~ are crucial players in tumor biology and that the modulation of their function is an indispensable requisite for the development of successful anti-tumor immune-therapies.

Mechanisms of T~reg~ suppression in tumors {#S1-2}
------------------------------------------

It was recently demonstrated that T~reg~ infiltrating different tissues have a specific gene signature ([@B16]), thus T~reg~ may use peculiar suppression mechanisms in response to microenvironmental stimuli. This specialization may represent the basis for designing immune interventions targeting specific T~reg~ functions in a given tissue while sparing systemic immune homeostasis. Even though a tumor T~reg~-specific gene signature has not been delineated yet, some mechanisms have been described to contribute to T~reg~ suppression in tumors, which can be clustered in three main types: surface molecules, enzymatic activities, and cytokines (Figure [1](#F1){ref-type="fig"}).

![**T~reg~ suppressive mechanisms in tumor microenvironment**. T~reg~ use different strategies to inhibit target cells within the tumor mass. Three types of T~reg~-related molecules can mediate these suppressive mechanisms: (1) surface molecules (upper panel); (2) enzymes (middle panel), and (3) cytokines (lower panel). (1) Among the surface molecules expressed by T~reg~, CTLA-4, LAG-3, Nrp-1, and RANKL have a well-demonstrated role in promoting tumor progression, mainly modulating DC activation and function. In particular CTLA-4 and LAG-3, binding to CD80/CD86 (B7-1/2), and MHCII respectively, significantly impair DC capacity to activate T~conv~. In addition CTLA-4 promotes IDO expression and the production of the pro-apoptotic metabolite kynurenine. Nrp-1 instead stabilizes T~reg~-DC contact, allowing T~reg~ to adequately suppress DC. Although the course of action of RANKL is not yet well defined, its expression is associated to tumor metastatization. (2) The two ecto-enzymes CD39 and CD73 generate from ATP pericellular adenosine, which is endowed with strong tolerogenic effects. Also cAMP, similarly to adenosine, interferes with T~conv~ activation and survival. Granzyme and perforin induce the apoptosis of target cells by cytolysis. (3) T~reg~ secrete several immune-modulatory cytokines, which could directly modulate T~conv~ functions (TGF-β, IL-10, and IL-35), or indirectly promote the establishment of pro-tumorigenic microenvironment (VEGF).](fimmu-04-00247-g001){#F1}

Both human and mouse T~reg~ constitutively express on their surface cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a co-inhibitory member of the CD28/B7 family, endowed with strong immune-regulatory properties ([@B17]). The relevance of CTLA-4 in regulating T~reg~ function was demonstrated in several settings, including autoimmune diseases and different tumor types ([@B18]). A comparative gene expression profile between T~reg~ and T~conv~ revealed that T~reg~ specifically up-modulate lymphocyte activation gene 3 (LAG-3) ([@B19]), a homolog of CD4, that binds to MHC class II on antigen-presenting cells (APCs). LAG-3 is upregulated in tumor-infiltrating T~reg~ and experiments with anti-LAG-3 mAb demonstrated that functional LAG-3 is required for maximal T~reg~ suppressive function ([@B20], [@B21]). T~reg~-DC interaction is also mediated by the transmembrane protein neuropilin-1 (Nrp-1), expressed on T~reg~ membrane, which ensures the stability of T~reg~-DC interaction and allows T~reg~ to efficaciously suppress DC ([@B22]). A study conducted on patients with early-stage cervical tumor showed that T~reg~ infiltrating the tumor-draining lymph node of patients with metastasis have a higher expression of several immune-modulatory molecules, including Nrp-1 ([@B23]). The receptor activator of nuclear factor-kB ligand (RANKL), member of the tumor necrosis factor family, was found to be highly expressed on T~reg~ isolated from tumor-bearing hosts, and substantial evidence indicates that RANKL expressed by T~reg~ is involved in the onset of metastasis in both mammary ([@B24]) and prostate tumors ([@B25]).

Regulatory T cell suppression may be mediated by enzymatic activities, such as CD39/CD73 ([@B26], [@B27]), granzyme B, and perforin ([@B28]). CD39 and CD73 are two ecto-enzymes that dephosphorylate extracellular ATP and generate pericellular adenosine, which in turn exerts a strong pro-tumorigenic role modulating the function of numerous tumor-infiltrating immune cells. CD73-deficient mice develop a stronger anti-tumor immune response compared to CD73-sufficient mice ([@B29]). T~reg~ are also able to control the proliferation and function of different immune cells via the Perforin pathway ([@B30]). In mouse models of melanoma, lymphoma, and acute myeloid leukemia it has been demonstrated that tumor-infiltrating T~reg~, but not naïve T~reg~, secrete high amounts of both perforin and granzyme B, which in turn induce NK and CD8^+^ T cell death ([@B28]).

Immunosuppressive cytokines, like TGF-β and IL-10, are critical players in T~reg~ biology, being involved in both their differentiation and suppressive potential, especially in tumors. T~reg~-derived TGF-β was found relevant in suppression of anti-tumor T cell response in both mouse ([@B31]) and human ([@B32], [@B33]) tumors. IL-10 is a well-known immunosuppressive mediator, and several pieces of evidence highlight the relevance of T~reg~-derived IL-10 in controlling inflammation at the mucosal interfaces such as gut and lung ([@B34], [@B35]). Despite these data, little information is available about the roles of T~reg~-derived IL-10 in tumor microenvironments. We have recently demonstrated that tumor-associated T~reg~ secrete high amounts of IL-10, which in turn impairs DC migration to the draining lymph nodes and the mounting of a specific anti-tumor immune response. This phenotype could be reverted by stimulating the receptor OX40 on the surface of intratumoral T~reg~. Indeed, OX40-triggered T~reg~ showed reduced secretion of IL-10 as a consequence of the down-modulation of the interferon regulatory factor 1 (IRF1), a transcription factor active in the IL-10 promoter ([@B36]). Another cytokine recently described as critical for the full T~reg~ suppressive function is IL-35, formed by Epstein--Barr-virus-induced gene 3 (Ebi3) and IL-12α (p35) ([@B37]). In two different mouse transplantable tumor models (melanoma and colon carcinoma), it was observed that T~reg~ secrete abundant IL-35, thus promoting the differentiation of induced IL-35-secreting T~reg~ ([@B37]). It is well known that tumor growth is associated with a consistent process of new angiogenesis in response to hypoxia. A circuit involving tumor hypoxia, T~reg~ recruitment, and angiogenesis has been recently discovered ([@B38]). In the hypoxic tumor microenvironment, the chemokine axis CCL28--CCR10 plays a determinant role in the recruitment of T~reg~, which secrete huge amounts of vascular endothelial growth factor (VEGF), further stimulating the new angiogenesis process and the establishment of a tolerogenic microenvironment ([@B38]).

Double effects of T~reg~ on prognosis {#S1-3}
-------------------------------------

Since their discovery, T~reg~ were considered one of the main obstacles for tumor clearance, according to their tolerogenic properties and their accumulation along tumor progression. In this view, several anti-tumor immune-therapies focus on T~reg~ depletion or inhibition, in order to "contrasuppress" T~reg~ inhibitory functions and to block the conversion of non-regulatory cells (non-T~reg~) into regulatory cells ([@B15]). Reduced T~conv~/T~reg~ ratio was observed in patients with pancreatic tumor ([@B39], [@B40]), breast cancer ([@B39]), ovarian cancer ([@B41]), Hodgkin lymphoma ([@B42]), and melanoma ([@B43]). Increased T~reg~ frequency is generally associated to advanced tumor stage and poor prognosis, as recently demonstrated in a study on ovarian cancer ([@B44]). In the ascites of patients with advanced tumor, the percentage of T~reg~ was increased compared to the ascites of patients with early-stage tumor. Same results were obtained with the mouse WF-3 transplantable ovarian tumor model, showing augmented percentages of T~reg~ in both spleen and tumor-associated cells of mice with advanced tumors, compared to naïve or mice with early lesions. In addition, the treatment of tumor-bearing mice with the T~reg~-depleting mAb PC61 (αCD25) reduced tumor growth and prolonged mice survival ([@B44]). Similarly, it has been demonstrated that T~reg~ number inversely correlated with the therapy outcome in melanoma patients treated with non-myeloablative chemotherapy, in combination or not with total body irradiation, followed by adoptive T cell transfer ([@B45]). Responder patients had a lower frequency of T~reg~ in peripheral blood compared to non-responder patients ([@B45]). A study conducted on patients affected by invasive ductal carcinoma showed a positive correlation among T~reg~, Th17, and tumor aggressiveness. These data imply that T~reg~ and Th17 cells may concomitantly expand during tumor progression, with T~reg~ mainly suppressing protective effector T cell proliferation while sparing Th17 proangiogenic activities, fostering cooperatively tumor progression, and the metastatic process ([@B46]).

Nevertheless, recent data, in particular tumor systems, point out that T~reg~ may exert a protective role for the host ([@B13], [@B47], [@B48]). The connection between tumor and inflammation is a well-assessed process ([@B49]), but now it is clearly emerging that the type of tumor-associated inflammation imprints the behavior of T~reg~, becoming detrimental or beneficial for the host. Type-1 inflammation, characterized by high concentration of IFN-γ and IL-12 and fully active cytotoxic cells, represents efficient anti-tumor immunity ([@B49]). In this setting, the inhibitory properties of T~reg~ may promote tumor escape and aggressiveness ([@B47]). On the contrary, immune responses dominated by cytokines like TNF-α, IL-1β, IL-6, IL-23, and IL-17 act as pro-tumoral mediators ([@B47]). In this environment T~reg~ may suppress a pro-tumoral inflammatory status, thus playing a protective role for the host ([@B47]).

These unexpected anti-tumoral T~reg~ properties were observed in patients with colorectal cancer (CRC) ([@B50]--[@B51][@B52]). In these patients, with different tumor stages, a better prognosis and an increased overall survival were associated with higher infiltration of FOXP3^+^ T cells compared to patients with a poor tumor outcome. These data suggested the hypothesis that FOXP3^+^ T cells could be considered as an independent prognostic factor for CRC. Following a strong activation, both conventional CD4^+^ ([@B53]) and CD8^+^ ([@B54]) lymphocytes up-regulate Foxp3 expression in colonic tissue. These observations indicated that the CRC prognosis positively correlated with non-regulatory FOXP3^+^ cells rather than to T~reg~. However *in vitro* suppression assays demonstrated that FOXP3^+^ cells, isolated from CRC tissues, were endowed with suppressive functions, confirming their nature as regulatory cells ([@B55]). In a recent study conducted on 65 patients with different stages of CRC, FOXP3 expression was systematically evaluated in both tumor-infiltrating lymphocytes and neoplastic cells, and was correlated to tumor progression and clinical-pathological features ([@B56]). From this study the notion emerged that high FOXP3 expression in tumor cells correlated with poor tumor outcome, compared to tumors poorly expressing FOXP3; on the contrary, no correlation was observed between CRC prognosis and FOXP3 expression by T cells ([@B56]).

A protective role of T~reg~ was also found in head and neck squamous cell carcinoma (HNSCC) ([@B57]). Univariate and multivariate analysis demonstrated that the locoregional control of the tumor was positively associated with CD4^+^FOXP3^+^ regulatory cell infiltration ([@B57]). However, also for this type of neoplasia, there are some discordant data regarding the role of T~reg~ in tumor progression. Indeed, another study showed that T~reg~ frequency and suppressive function were higher in the peripheral blood of tumor-bearing patients than in healthy volunteers ([@B58]).

The discrepancies observed in these studies may be due to the number of patients included, different strategies of analysis and non-homogeneity of tumor samples (stage, metastasis, etiology). Certainly, to properly define the role of T~reg~ in tumor outcome, the new studies should take into account the tumor stage and the related inflammatory features, depending on the anatomical localization. In general, those tumors arising from chronic inflammation, almost at their initial stage, can benefit from the suppressive properties of T~reg~. In fact, during the inflammatory process, T~reg~ highly accumulate in the site of inflammation such to prevent exacerbated immune responses and tissue damage, which are the prelude to neoplastic transformation. On the contrary, in the presence of an established tumor, T~reg~ may reduce anti-tumor immunity thus favoring tumor escape. A more specific definition of T~reg~ contribution in tumor development and progression is desirable for the design of new and more effective immunotherapies, allowing the discrimination among tumors that will benefit or not from T~reg~ depletion/inhibition.

Evidence for pT~reg~ or tT~reg~ Accumulation in Tumors {#S2}
======================================================

Distinguishing features of pT~reg~ and tT~reg~ {#S2-4}
----------------------------------------------

Many efforts have been recently addressed to the identification of phenotypic, molecular, and functional features distinguishing tT~reg~ and pT~reg~, besides their site of origin ([@B11]). Some markers have been proposed to distinguish pT~reg~ and tT~reg~, even though with some limitations: the initial enthusiasm for the suggestion of Helios as able to identify tT~reg~ ([@B59]) has been soon moldered by the observation of Helios expression in pT~reg~ ([@B60]); the recent finding of the Nrp-1 as a marker of tT~reg~ ([@B61], [@B62]) has application limited to murine cells, being not expressed on human T~reg~ ([@B63]). Several attempts have been conducted to identify genetic ([@B64]--[@B65][@B66]) and/or epigenetic signatures distinguishing pT~reg~ and tT~reg~. The T~reg~-specific demethylated region (TSDR) is involved in the stable commitment of the T~reg~ lineage, and controversy still remains on whether iT~reg~ or pT~reg~ can efficiently demethylate this region and become fully committed T~reg~ ([@B66]--[@B67][@B68][@B69]). Despite this growing amount of information, distinguishing the relative contribution of pT~reg~ and tT~reg~ to immune suppression in physiological and pathological conditions remains hard. However, some pieces of evidence have accumulated in the last years that speak in favor of tT~reg~ or pT~reg~ prevalence or concomitance in tumors.

Evidence for tT~reg~ accumulation in cancer {#S2-5}
-------------------------------------------

One of the first attempts to distinguish between pT~reg~ conversion and tT~reg~ expansion in cancer was pursued by Bui and colleagues who adoptively transferred CD4^+^CD25^+^ cells, mixed at 1:10 ratio with CD25-depleted Thy1.1-congenic splenocytes, into immunodeficient mice bearing a progressive sarcoma ([@B70]). The analysis performed 10 days after tumor injection showed that the vast majority (around 80%) of tumor-infiltrating CD4^+^CD25^+^ cells derived from expansion/recruitment of the transferred T~reg~, rather than from conversion of non-T~reg~. This and other reports, appeared in the "pre-Foxp3" era, were biased by the idea that CD25 was the most stringent T~reg~ marker and that CD25-depleted cells represented a suitable precursor population to efficiently detect *de novo* generation of pT~reg~. However, subsequent studies have demonstrated that the CD25^+^ subset of Foxp3^−^ T~conv~ is enriched in pT~reg~ precursors ([@B69], [@B71]), thus the extent of pT~reg~ differentiation from CD25-depleted cells represents probably an underestimation of the actual contribution of pT~reg~ induction in the tumor context. Other authors have shown that tT~reg~ may dominate pT~reg~ not only quantitatively but also qualitatively, in terms of suppressive function: indeed, IDO^+^ plasmacytoid dendritic cells, derived from mouse tumor-draining lymph nodes, were capable to induce Foxp3^+^ pT~reg~ at very high levels but were unable to activate the suppressive function of these cells to an extent comparable to tT~reg~ ([@B72]). Many studies have clearly shown T~reg~ proliferation (in terms of *de novo* DNA synthesis and/or cell division) in tumor-bearing mice or cancer patients, thus indirectly supporting the idea that expansion of pre-existing tT~reg~ might prevail over pT~reg~ differentiation in building the tumor-associated T~reg~ pool. For instance, T~reg~ have been shown to incorporate high levels of BrdU in tumor-draining lymph nodes and at cancer sites in several experimental models ([@B73], [@B74]). A study conducted in patients with multiple myeloma showed that the TREC content in naive cells was significantly lower in T~reg~ (identified as CD4^+^CD25^high^ cells) than CD4^+^CD25^−^ or CD25^low^ cells, suggesting that the T~reg~ pool mainly derived from peripheral expansion rather than recent thymic emigration ([@B75]). However, the observation of high T~reg~ proliferation at tumor sites cannot be considered as an unequivocal proof of tT~reg~ prevalence over pT~reg~, since both subsets could be endowed with the same proliferative potential *in vivo*. Indeed, several pieces of evidence indicate that conversion and proliferation may represent uncoupled and independent events (see pTreg Development and tTreg Expansion as Independent Processes).

Evidence for pT~reg~ induction in cancer {#S2-6}
----------------------------------------

Some studies support the idea that pT~reg~ conversion actually occurs in tumor-bearing hosts at higher efficiency than in physiological conditions, even if controversy still exists on whether pT~reg~ may prevail numerically over tT~reg~ at the tumor site. We have in the past demonstrated that thymectomized and CD25-depleted mice, subsequently transplanted with carcinoma cells, showed a significantly higher T~reg~ recovery in tumor-draining than in contralateral lymph nodes, suggesting that in tumor-bearing mice the T~reg~ pool might be replenished mostly by newly derived pT~reg~ than by proliferation of residual T~reg~. To prove this possibility, CD25-depleted CD4-purified T cells were transferred into immunocompetent, Thy1.1-congenic, CT26 tumor-bearing mice. In this setting, we could show that the transferred cells acquired CD25 and Foxp3 at significantly higher levels in draining lymph nodes, compared to contralateral lymph nodes of tumor-bearing mice, or to the lymph nodes of tumor-free mice ([@B76]). This result clearly showed that tumor progression actively promoted the conversion of non-regulatory precursors into pT~reg~. Some tumor-derived molecular signals were found to be involved in tumor-associated conversion. For instance, in different mouse models, tumor cells have been shown to induce *in vitro* T~reg~ conversion through TGF-β, and TGF-β neutralization abrogated T~reg~ accumulation at the tumor site ([@B77]). Human leukemic cells converted *in vitro* non-T~reg~ into T~reg~ through the tumor cell-restricted IDO activity, and IDO blockade prevented pT~reg~ induction *in vivo* in a leukemia mouse model ([@B78]). A confirmation of extensive pT~reg~ infiltration in murine tumors has been recently obtained thanks to the recent discovery of Nrp-1 as a tT~reg~-restricted marker ([@B61], [@B62]). The analysis of Nrp-1 expression has indeed revealed that Nrp-1-negative *bona fide* pT~reg~ cells were significantly enriched at tumor site compared to spleen, ranging around 40--90% of total tumor-infiltrating T~reg~ depending on the tumor type ([@B61]). These Nrp-1-negative cells also presented a gene signature (Helios^low^, SWAP-70^low^, and Dapl1^high^) compatible with the pT~reg~ identity ([@B61]). Unfortunately, human T~reg~ do not express Nrp-1 ([@B63]), thus this marker cannot be used to estimate the relative contribution of tT~reg~ or pT~reg~ in human cancers.

Developmental and Functional Relations between pT~reg~ and tT~reg~ in Cancer {#S3}
============================================================================

pT~reg~ development and tT~reg~ expansion as independent processes {#S3-7}
------------------------------------------------------------------

Many attempts have been made to understand whether tT~reg~ accumulation and pT~reg~ development are mutually exclusive or rather cooperative in establishing immune suppression. The evidence that tT~reg~ may "educate" T~conv~ to convert into T~reg~ through the secretion of cytokines, such as TGF-β and IL-10 ([@B79]), may support the latter possibility. This event would generate a cascade of suppressive function transmitted from T~reg~ to bystander cells, establishing a loop of immunosuppression, reminiscent of a phenomenon called as "infectious tolerance" ([@B80]). Zhou and coworkers have addressed this issue in the tumor setting, and have demonstrated that tumor-antigen-specific pT~reg~ could indeed arise from T~reg~-depleted cells (adoptively transferred in mice carrying the cognate antigen-expressing tumor), but that the extent of pT~reg~ induction was not affected by the concomitant presence of tT~reg~, either exogenous (adoptively co-transferred) or endogenous (pre-existing in the host) ([@B81], [@B82]). This result indicated that tT~reg~ and pT~reg~ accumulate in tumors in a reciprocally independent fashion and that "infectious tolerance" may play minor roles in shaping the tumor-associated T~reg~ pool.

A comprehensive scenario of T~reg~ accumulation in tumors should take into account, beside *de novo* conversion, the active proliferation of not only tT~reg~ but also pT~reg~. Proliferation plays opposite roles in the differentiation of T~conv~ into pT~reg~ *versus* the expansion of already differentiated pT~reg~. Regarding the former aspect, we have demonstrated that T~conv~ proliferation was not required for their conversion into pT~reg~, since CD25^+^Foxp3^+^ cells could develop in tumor-bearing mice from CD25-depleted cells treated with an anti-proliferative agent ([@B76]). A seminal study by Kretschmer and colleagues showed that T~conv~ proliferation was not only dispensable but also detrimental to conversion: indeed, low levels of T cell proliferation, in conditions of suboptimal antigen presentation, lack of co-stimulation, and IL-2 paucity, favored TGF-β-mediated pT~reg~ induction, thus suggesting that an inverse relationship might exist between T~conv~ proliferation and conversion into pT~reg~ ([@B83]). However, once developed, pT~reg~ promptly proliferated in response to experimental antigens ([@B83]) and, more importantly, in response to tumor antigens ([@B81], [@B82]). Experiments performed in CNS1-mutated mice, which are genetically unable to generate pT~reg~, have shown that pT~reg~ and tT~reg~ may occupy distinct "niches": indeed, the efficiency of pT~reg~ differentiation from T~conv~ was higher when those T~conv~ were co-transferred, in lymphopenic recipients, with a CNS1-deficient (non-containing pT~reg~) compared to a CNS1-sufficient (containing pT~reg~) counterpart, suggesting that not only the tT~reg~ pool, but also the pT~reg~ niche, may be controlled by autonomous homeostatic mechanisms ([@B84]).

Division of labor between tT~reg~ and pT~reg~ in cancer {#S3-8}
-------------------------------------------------------

Both tT~reg~ and pT~reg~ have been generally recognized as immune suppressive cells in a variety of *in vivo* and *in vitro* experimental settings ([@B12]). However, whether the two subsets are endowed with peculiar activities remains unclear and is a matter of intense investigation.

Gene expression profiling revealed that the pT~reg~ and tT~reg~ signatures were mostly overlapping but also presented some differentially expressed genes, encoding for proteins involved in T~reg~ suppressive function, suggesting that pT~reg~ may preferentially exploit different molecules and related mechanisms to exert suppression ([@B64]--[@B65][@B66]). The Nrp-1 itself is not only a marker discriminating murine tT~reg~ from pT~reg~, but also plays a role in T~reg~ suppression: since this molecule prolongs T~reg~ interactions with immature dendritic cells, tT~reg~ may benefit from this pathway in preferentially modulating dendritic cell and cognate T cell activation ([@B22]). Many data suggest that pT~reg~ may be specialized suppressors of immune responses at interfaces with external environments, such as airways, gut, and maternal-fetal interface ([@B64], [@B84]--[@B85][@B86][@B87]). Of note, a peculiar T~reg~ suppressive molecule, IL-10, plays crucial roles at environmental interfaces, therefore pT~reg~ may perform their specialized activity through IL-10 secretion ([@B34], [@B88]). IL-10 is critically involved in the establishment of tumor-associated immune suppression, and we have clearly demonstrated IL-10 production by around 40% of tumor-infiltrating T~reg~ in murine transplanted tumors ([@B36]). It would be interesting to understand whether the fraction of IL-10-producing T~reg~ is enriched in pT~reg~, rather than tT~reg~, in tumors. One study has directly addressed the issue of induced T~reg~ functional specialization in tumors, by generating *in vitro* tumor-specific iT~reg~ and co-culturing these cells, or tT~reg~ as control, with NK cells: these authors found that iT~reg~ and tT~reg~ equally suppressed IL-2-induced NK activation, but only iT~reg~ were endowed with the surprising ability not to suppress, but to enhance, NK cytotoxicity induced by tumor target cell contact ([@B89]). This observation may speak in favor of differential roles played by tT~reg~ and pT~reg~ in cancer, with the former more involved in preventing target cell-independent, and possibly self-directed, unwanted immune responses, and the latter concurrently enhancing tumor-specific immunity.

This division of labor may result in the progressive shaping of the immune response toward an effective anti-tumor immunity with minimal side effects. Such dichotomy is also reminiscent of the double role played by T~reg~ in different cancers, according to the hypothesis that high T~reg~ frequency is associated to poor or good prognosis in non-inflammatory or inflammatory cancer onset, respectively ([@B13], [@B47]). In the former case, i.e., non-inflammatory cancers in which protective type-1 responses are suppressed by high T~reg~ infiltration, T~reg~ may mainly recognize tumor-associated self-antigens, and mostly include tT~reg~; conversely, in the case of inflammatory cancers, related to chronic low-dose type-17 cytokines, which are typical of mucosal tissues, high numbers of pT~reg~ may suppress pro-tumoral inflammation through IL-10, relevantly produced by pT~reg~ at those sites. We are tempting to speculate that tT~reg~ may dominate in suppressing anti-tumor type-1 responses, while pT~reg~ may prevail in shaping pro-tumor type-2 and type-17 inflammatory responses. Notably, the prototypical example of an inflammation-related tumor in which T~reg~ accumulation associates to good prognosis is CRC ([@B50]), developing in the gastrointestinal mucosa, in which immune tolerance is under the control of pT~reg~ ([@B84]).

Antigen specificity of tT~reg~ versus pT~reg~ in cancer {#S3-9}
-------------------------------------------------------

Antigen recognition may play a crucial role in dictating whether tT~reg~ or pT~reg~ will prevail in the tumor context. Controversy still exists on the antigen specificity of these two populations. On the one side, tT~reg~ are generally believed to recognize self-antigens encountered during thymic selection ([@B90]). On the other side, pT~reg~, deriving from T~conv~, are thought to display the same TCR repertoire of T~conv~ and thus to mainly recognize foreign antigens. Indeed, only a small overlap exists between TCR repertoires of pT~reg~ and tT~reg~ ([@B66]), and pT~reg~ are believed to recognize non-self-antigens such as commensal microbiota, allergens, and fetal alloantigens ([@B84], [@B87]).

Tumor cells can express a variety of antigens that can be broadly classified into: (i) self-antigens physiologically expressed as in the tissue of origin, (ii) self-antigens aberrantly expressed, in terms of expression level, developmental stage, or histotype (called tumor-associated antigens or TAAs), and (iii) neo-antigens uniquely expressed by tumor cells, mostly derived from oncogenic mutations (named tumor-specific antigens or TSAs). Based on the above considerations, self-antigens and TAA should be recognized by tT~reg~, while TSA would induce and activate pT~reg~. However, a complex picture arises from studies analyzing the TCR specificity of tumor-associated T~reg~.

### T~reg~ can recognize TAA and TSA in tumors {#S3-9-1}

In different tumor models, TCR-transgenic T~reg~ have been shown to promptly proliferate in response to the cognate antigen specifically expressed by tumor cells, suggesting that T~reg~ can undergo tumor-antigen-driven activation and expansion ([@B74], [@B81], [@B82], [@B91]). Antigen presentation in the tumor context may favor T~reg~ expansion: in a mouse model of spontaneous prostate cancer, an efficient T~reg~ induction/expansion occurred only when TCR-transgenic, antigen-specific CD4 T cells encountered the cognate antigen expressed in the context of prostate cancer cells, rather than non-transformed cells or viral vector-infected cells ([@B91]). In this model, TAA-specific T~reg~ were recognized as pT~reg~ induced *in vivo* in a TGF-β-independent fashion.

This evidence of TAA-responding T~reg~ has been confirmed in human tumors. CD4 clones derived from cancer patients resulted to be regulatory cells and to recognize peptides derived from TAAs, such as LAGE1 ([@B92]), ARTC1 ([@B93]), TRAG-3, NY-ESO-1 ([@B94]--[@B95][@B96]), Melan-A ([@B97]), survivin, TRP1, and gp100 ([@B94]) in melanoma patients, and WT-1 in leukemia patients ([@B98]). By using MHCII/peptide tetramer technology, other authors failed to detect T~reg~ specific for NY-ESO-1 in the peripheral blood of ovarian cancer patients ([@B99]). Bonertz et al. developed an *in vitro* system to screen the suppressive function of T~reg~ in response to single peptides and, with this approach, could detect T~reg~ specific for several TAA in the peripheral blood of colon carcinoma patients but not in healthy donors; notably, T~reg~ depletion *in vitro* unveiled TAA-specific T~conv~ responses ([@B100]).

The possibility that tumor-associated T~reg~ may recognize not only TAA but also TSA is demonstrated by the observation that T~reg~ specific for exogenous viral antigens, acting as TSA, may arise in virus-related cancers. T~reg~ clones specific for human papilloma virus (HPV), and suppressing the cognate antigen-directed T cell response, have been obtained from tumor-draining lymph nodes and tumor biopsies of cervical cancer patients ([@B101]). T~reg~ clones specific for antigens of the Epstein--Barr virus (EBV), associated to several hematological and solid malignancies, can be generated from the peripheral blood of healthy donors ([@B102]).

### T~reg~ can recognize self-antigens in tumors {#S3-9-2}

Several data in mouse models confirm that T~reg~ responding to self-antigens can play a role in suppressing the anti-tumor responses. Immunization with serologically defined auto-antigens was found to enhance tumor growth in different mouse models, and this event was dependent on the expansion of T~reg~ responding to those self-antigens ([@B103]). This study confirmed that self-antigens-specific T~reg~ could suppress anti-tumor immunity, but did not explore the T~reg~ response to self-antigens expressed by tumor cells themselves during tumor progression. This issue has been instead addressed in an experimental model in which a foreign antigen, artificially expressed in transgenic mice under tissue-specific promoter, was seen (peripherally and/or thymically) by the immune system as a self-antigen and elicited the generation of a pool of memory T~reg~ specific for that antigen ([@B74]). If those mice were injected with the cognate antigen-bearing tumor, the memory T~reg~ pool specific for that self-antigen was hugely expanded in tumors and tumor-draining lymph nodes, confirming that self-specific T~reg~ can respond to self-antigens expressed by tumor cells ([@B74]). A seminal paper has recently reported the immunoscope analysis of T~reg~ infiltrating spontaneous prostate tumors in a mouse transgenic model, and described the clonal enrichment of a single T~reg~ specificity that was directed not to a unique TSA but to a self-antigen expressed also by normal prostate cells ([@B104]). The development of T~reg~ specific for peripheral tissue-restricted self-antigens occurred in the thymus under the control of the Aire molecule, which allows the expression of peripheral antigens in thymic epithelial cells ([@B104]). These findings clearly demonstrate that T~reg~ can recognize self-antigens in cancer and suggest that maintaining self-antigen expression may help transformed cells to overcome the immune surveillance through self-specific T~reg~ expansion.

### Repertoire analysis as an estimation of pT~reg~/tT~reg~ balance {#S3-9-3}

The direct comparison between the repertoires of tumor-associated T~reg~ and T~conv~ may help understanding the processes underlying T~reg~ enrichment in cancer. Some authors have reported that the analysis of TCR diversity (performed with the immunoscope technology) showed that T~reg~ infiltrating murine transplanted tumors displayed a biased TCR repertoire toward "public" CDR3 sequences (i.e., shared by different mice), suggesting T~reg~ intra-tumor clonal expansion driven by the recognition of dominant antigens ([@B105]). Also tumor-infiltrating activated T~conv~ showed a biased TCR repertoire, but it was distinct from the T~reg~ spectrum, and the minimal overlap between the two subsets was mainly confined to "private" specificities ([@B105]). By using a similar approach, others have reported distinct and not overlapping TCR repertoires of T~reg~ and T~conv~ infiltrating prostate tumors in a genetically engineered mouse model of spontaneous prostate carcinogenesis ([@B104]). Lack of overlap between T~conv~ and T~reg~ repertoires was also found in tumors and tumor-draining lymph nodes in a mouse model of chemical carcinogenesis ([@B106]). Overall, the lack of overlap between T~reg~ and T~conv~ has been interpreted in many cases as the result of negligible pT~reg~ conversion at the tumor site; however, pT~reg~ and tT~reg~ may share more specificities than expected, since tT~reg~-associated antigens may preferentially drive T~conv~ fate decision toward the conversion into pT~reg~ rather than toward the conventional activation; moreover, already established pT~reg~ may then undergo intra-tumor clonal expansion together with tT~reg~ in response to the same antigens. Therefore, the overall overlap between T~conv~ and T~reg~ specificities may not accurately estimate the extent of pT~reg~ induction in tumors. Indeed, in one study performed in advanced melanoma patients, TAA-specific TCRs, expressed by tumor T~reg~ clones, could be detected in both T~reg~ and T~conv~ populations, demonstrating that TAA-specific T~reg~ may be comprised of pT~reg~ derived from the conversion of T~conv~ ([@B95]).

Indirect data support the notion that TAA-specific T~reg~ may contain pT~reg~. TAA-specific T~reg~ clones, obtained from patients with advanced melanoma, suppressed *in vitro* the cognate antigen-specific T cell response, but produced high levels of Th1 and/or Th2 cytokines ([@B95]), and showed low FOXP3 expression and TSDR demethylation, indicating that these cells may represent an incompletely uncommitted T~reg~ population, which more likely belongs to the pT~reg~ than to the tT~reg~ pool ([@B95]).

A recent study has directly evaluated the consequences of pT~reg~ and tT~reg~ antigen specificities in tumor-bearing hosts. Indeed, Schreiber et al. have shown that, if purified polyclonal tT~reg~ and T~conv~, differentially labeled with green or red fluorescence, were co-transferred in CD4-null mice, the tT~reg~ progeny exceeded the newly T~conv~-derived pT~reg~ population in tumor-draining lymph nodes as well as in the spleen; conversely, when transgenic, tumor-antigen-specific, tT~reg~ and T~conv~ were injected, tT~reg~ and pT~reg~ reached comparable frequencies in tumor-draining lymph nodes ([@B107]). These results suggest that tT~reg~ and pT~reg~ are mostly specific for self- or tumor-antigens respectively, and that the balance between pT~reg~ and tT~reg~ may be fine-tuned by the relative prevalence of TSAs versus self-antigens expressed by tumor cells.

Heterogeneity and Plasticity of tT~reg~ and pT~reg~ {#S4}
===================================================

T~reg~ heterogeneity in cancer: Relations with the pT~reg~/tT~reg~ dichotomy {#S4-10}
----------------------------------------------------------------------------

During the latest years, it has become increasingly clear that T~reg~, meant as Foxp3-positive cells, are not a homogeneous lineage, but rather represent a mixture of subpopulations. Indeed, beside the tT~reg~/pT~reg~ distinction based on their developmental origin, diverse T~reg~ subsets can be identified endowed with peculiar features in terms of suppression, proliferation, and stability, even though not properly classifiable as developmentally distinct lineages (Figure [2](#F2){ref-type="fig"}). Tumor microenvironmental signals may differentially affect these subsets, thus shaping T~reg~ heterogeneity to the advantage of tumor progression.

![**Functional dynamics of tT~reg~ and pT~reg~ in cancer**. This picture summarizes development, heterogeneity, plasticity, antigen specificity, and function of pT~reg~ and tT~reg~ in cancer. Activated T~reg~, which are epigenetically committed and mostly self- and TAA-specific, can transiently lose Foxp3 without methylating TSDR thus becoming latent T~reg~; in some conditions, they can acquire T-bet expression thus becoming specialized suppressors, detrimental to the anti-tumor type-1 response. Activated T~conv~, mostly foreign (TSA) antigen-specific, can promiscuously express Foxp3 without demethylating TSDR. However, a fraction (CD25^+^, or CD39^+^) of activated T~conv~ can convert into pT~reg~, progressively moving from an uncommitted to a committed stage. Through IL-10, committed pT~reg~ can suppress pro-tumoral inflammatory and type-17 responses, thus exerting beneficial roles for the host in some cancer types. In some contexts, uncommitted pT~reg~ (and possibly activated T~conv~) can move back to exT~reg~ stage, acquiring the ability to produce inflammatory cytokines. Therefore, in some tumors such as colon cancer, Th17-like T~reg~ may foster type-17 inflammation thus supporting tumor growth; in other tumor contexts, Th1-like T~reg~ can favor type-1 responses that rather block tumor growth. Green, cells specific for self-antigens and TAA; light blue, cells specific for foreign antigens including TSA. Yellow dash, demethylated TSDR; blue dash, methylated TSDR. Red "F" in yellow circles, stable Foxp3; yellow "F" in empty circles, unstable Foxp3. Dashed arrows, unclear events. Orange rounded arrows, proliferation in the tT~reg~ or the pT~reg~ homeostatic niche. Light green frames, conditions in which T~reg~ are beneficial to the host; light orange frames, conditions in which T~reg~ are detrimental to the host.](fimmu-04-00247-g002){#F2}

### T~reg~ stability and epigenetic commitment in cancer {#S4-10-4}

Foxp3 inherent stability, rather than Foxp3 expression in a given moment and tissue, is intimately linked to an actual commitment to the T~reg~ lineage and therefore to the maintenance of immune suppression. Pioneer studies have demonstrated that Foxp3 stability is strictly related to an epigenetic imprinting of CpG demethylation in the TSDR region of the *Foxp3* locus ([@B67], [@B86], [@B108]). TSDR demethylation was then recognized as the mechanism featuring the distinction between committed (demethylated) and uncommitted (methylated) T~reg~, irrespective of Foxp3 expression ([@B9]). Controversy exists on whether pT~reg~ show complete or partial TSDR demethylation and can then be considered as committed T~reg~. Many studies show that iT~reg~ have a partially or completely methylated TSDR ([@B9], [@B67]--[@B68][@B69]), while pT~reg~ have been described as TSDR-demethylated ([@B68]), TSDR-methylated ([@B66]), or as a mixed population of stable and unstable cells, characterized by CD25 high or low expression respectively ([@B69]).

Few data exist on the extent of TSDR demethylation in tumor-associated T~reg~. The frequency of TSDR-demethylated cells is higher in peripheral and intratumoral leukocytes of lung, colon, prostate, or breast cancer patients, in relation to a higher T~reg~ frequency as determined by flow cytometry or immunohistochemistry ([@B109]). Of note, the extent of TSDR demethylation in CRC patients was only slightly higher than in healthy volunteers, in contrast to the significantly increased T~reg~ frequency in these samples shown by previous studies ([@B110], [@B111]). This discrepancy may be explained with the peculiar nature of this inflammation-related and mucosal tissue-located cancer, in which the inflammatory response may specifically involve pT~reg~, possibly containing more uncommitted (TSDR-methylated) cells than tT~reg~.

The evaluation of TSDR demethylation has been used as a reliable analytical tool for the estimation of committed T~reg~ in some tumor conditions and therapies. An increased frequency of epigenetically committed (TSDR-demethylated) T~reg~ has been determined in tumor-infiltrating cells of ovarian, colorectal, and bronchial cancers compared to non-tumoral tissue counterparts ([@B112]). TSDR demethylation was decreased in the peripheral blood of metastatic renal carcinoma patients receiving tumor vaccination ([@B113]), and increased in patients treated with dendritic cell vaccination and cytokine therapy ([@B114]).

### T~reg~ functional dynamics in cancer {#S4-10-5}

The idea of Foxp3 as the master transcription factor of T~reg~ lineage has been challenged by the observation that some T~reg~ features are Foxp3-independent, and that Foxp3 plays T~reg~-unrelated functions ([@B115]). This is especially true for human FOXP3-positive cells, since human activated T~conv~ can transiently express this transcription factor that acts as an intrinsic T cell regulator ([@B116]). The concomitant analysis of CD45RA and FOXP3 in human T~reg~ in both physiological and pathological contexts allowed delineating a classification into three subsets: CD45RA^+^FOXP3^low^ resting T~reg~ (rT~reg~), CD45RA^−^FOXP3^low^ non-T~reg~, and CD45RA^−^FOXP3^high^ (CD45RO^+^) activated T~reg~ (aT~reg~), endowed with different potentials of proliferation, suppression, stability, and plasticity ([@B117]). Whether each subset mainly contains tT~reg~ or pT~reg~ is unclear. While rT~reg~ were recognized as CD31^+^ recent thymic emigrants, thus belonging to the tT~reg~ pool, aT~reg~ can be considered as a mixed population of activated tT~reg~ (derived from rT~reg~) and pT~reg~ (derived from non-T~reg~ or T~conv~). The CD45RA^−^FOXP3^low^ non-T~reg~ subset may represent a mixture of activated T~conv~ (promiscuously and unstably expressing FOXP3), latent T~reg~ (transiently downregulating FOXP3), and recently converted pT~reg~ ([@B117]).

The three human T~reg~ subsets can be differentially expanded in distinct pathologies. In conditions characterized by exacerbated immune responses, such as autoimmune diseases, rT~reg~ and non-T~reg~ are expanded; conversely, in diseases associated to immune unresponsiveness, such as sarcoidosis, the aT~reg~ subset is instead enriched in the peripheral blood ([@B117]). The tumor context, which conceivably belongs to the latter category, should be characterized by aT~reg~ expansion. In line with this hypothesis, CD45RO^+^FOXP3^high^ aT~reg~ were found significantly expanded in the peripheral blood, and much more at the tumor site, in patients with malignant melanoma ([@B118]). Also the non-T~reg~ and the rT~reg~ fractions were increased, but only in the peripheral blood, in cancer patients compared to healthy controls, and both subsets positively correlated with tumor progression ([@B118]). The non-T~reg~ pool produced some IFN-γ and its frequency returned to normal levels after tumor removal, thus probably representing aberrantly activated T~conv~, or T~reg~ with attenuated FOXP3 activity ([@B118]). A much deeper knowledge on T~reg~ dynamics in cancer is needed to better understand the role played by each specialized component in suppressing anti-tumor type-1, or pro-tumor inflammatory, responses.

### T~reg~ subsets specified by functional/developmental markers {#S4-10-6}

Several surface or intracellular markers have been suggested to identify T~reg~ subsets endowed with peculiar abilities other than suppressive functions. A portion of human T~reg~ with an effector/memory-like phenotype ([@B26], [@B119], [@B120]) expresses CD39, which has been proposed as a target to enrich human suppressive T~reg~ ([@B119]). CD39 was found overrepresented in peripheral and tumor-infiltrating T~reg~ from HNSCC, and was further increased in patients with advanced-stage disease or after radiochemotherapy ([@B120], [@B121]). CD39 is also expressed by a T~conv~ subset, which produces lower levels of pro-inflammatory cytokines than the bulk T~conv~ population, and is more prone to convert, at least *in vitro*, into T~reg~ ([@B120]). Both CD39^+^ T~reg~ and CD39^+^ T~conv~ were enriched in peripheral blood, and further increased at tumor site, in HNSCC patients, and a positive correlation existed between frequencies of these two populations ([@B120]). Therefore, these data suggest that tumor-associated CD39^+^ T~conv~ may represent a reservoir of CD39^+^ T~reg~ precursors. As a consequence, it could be suggested that CD39^+^ T~reg~ may include both tT~reg~ and pT~reg~, and that both T~reg~ subsets can exploit the CD39-mediated suppressive mechanisms of ATP degradation and adenosine generation.

Not only the functional arms of suppression, but also the activation requirements may differ in tT~reg~ and pT~reg~: for instance, TNFR2 expression is needed to activate tT~reg~ but not iT~reg~ suppressive ability in experimental colitis ([@B122]). Of note, TNFR2-positive T~reg~ have been found enriched in murine tumors, in association with a higher suppressive ability, *ex vivo*, in the standard suppression assay ([@B123]). In a mouse model of metastatic melanoma, TNF-α caused enhanced tumor progression through the TNFR2-mediated T~reg~ expansion at the site of metastasis ([@B124]). These data suggest that TNFR2 expression may label tumor-infiltrating T~reg~ of thymic origin, and that TNF-α at the tumors site may preferentially expand and activate tT~reg~. Supporting the idea that tT~reg~ may represent more stable cells, TNFR2 was found to be involved in the maintenance of Foxp3 stability in mouse models of inflammation ([@B125]). Also in human peripheral blood, CD25 and TNFR2 co-expression identifies cells highly expressing FOXP3, showing an effector/memory phenotype and strong suppression, *ex vivo* ([@B126]). The TNF-α/TNFR2 pathway may amplify T~reg~ activation also through the induction of a NF-kB-driven transcriptional program enriched for other members of TNF superfamily, such as 4-1BB, FAS, and OX40 ([@B127]).

The early idea that Helios could differentiate tT~reg~ from pT~reg~ ([@B59], [@B128]) prompted the use of this marker in delineating tT~reg~ accumulation in cancer. The vast majority of tumor-infiltrating T~reg~ were found to express Helios in a mouse model of glioblastoma ([@B129]), in glioblastoma multiforme patients ([@B129]), and renal cell carcinoma patients ([@B130]). However, the value of Helios as univocal marker of tT~reg~ has been questioned by other studies that showed Helios also expressed in pT~reg~ ([@B60], [@B131]), and in association to T~reg~ suppression ([@B128], [@B131]) and commitment. Indeed, Helios^−^FOXP3^+^ cells freshly isolated from healthy donors or autoimmune disease patients showed decreased TSDR demethylation compared to Helios^+^FOXP3^+^ ([@B132], [@B133]), and also displayed a higher plasticity in terms of cytokine production ([@B133]). In a murine transplanted tumor model, tumor-infiltrating T~reg~ were enriched in Helios^+^ cells, representing the subset with the highest proliferative potential (as shown by Ki67 staining) ([@B131]). In summary, the well-recognized enrichment of Helios^+^ T~reg~ in several human and mouse tumors may be attributed, rather than to preferential attraction and expansion of tT~reg~, to the tumor-driven local activation and/or commitment of both tT~reg~ and pT~reg~.

Specialization and plasticity of tT~reg~/pT~reg~ in cancer {#S4-11}
----------------------------------------------------------

It is now well established that T~reg~ (or better, their specific subsets) adapt their molecular programs to optimize their *in vivo* suppressive function in distinct inflammatory milieus, which may be alternatively dominated by Th1, Th2, Th17, or T~FH~ responses. Strikingly, these T~reg~ specialized programs are orchestrated by the same transcription factors that drive the polarization of the targeted T-helper subset: therefore, T-bet, IRF4, Stat3, and Bcl6 expression are respectively and selectively required for the T~reg~ specialized suppression of Th1 ([@B134], [@B135]), Th2 ([@B136]), Th17 ([@B137]), and T~FH~ ([@B138], [@B139]) responses. Indeed, by acquiring master T-helper genes, T~reg~ may gain the expression of chemokine receptors driving the recruitment of specialized T~reg~ into inflamed tissues. However, in some contexts, T~reg~ (or, again, some T~reg~ subsets) can express not only T-helper-related transcription factors and migratory molecules, but also cytokines such as IFN-γ or IL-17, thus turning from specialized suppressors into so-called Th1-like or Th17-like T~reg~ that may rather contribute to inflammation ([@B140]). Some data, mostly from mouse experimental models, suggest that such T~reg~ plasticity is not a lineage reprograming of committed T~reg~, which appear instead quite stable; rather, Th1-like or Th17-like T~reg~ may derive from uncommitted cells expanded in inflammatory conditions ([@B69], [@B141]). However, other studies have shown that in both mouse and human pathologies T~reg~ can produce relevant amounts of type-1 and type-17 cytokines even though preserving Foxp3 expression ([@B142]--[@B143][@B144][@B145][@B146]).

### Th17-like T~reg~ in cancer {#S4-11-7}

Regulatory T cells may shift to a Th17-like phenotype in inflamed microenvironments dominated by type-17 cytokines, thus favoring, rather than suppressing, pro-tumoral mechanisms of chronic inflammation. According to this idea, human T~reg~ have been found to spontaneously secrete IL-17 in the intestine of patients carrying inflammatory bowel disease ([@B145], [@B147]) and colon carcinoma ([@B147]). In epithelial ovarian cancer, a malignancy associated to chronic inflammation, T~conv~ were found to secrete high levels of IL-17 (and other cytokines) when cultured *ex vivo* with IL-2; under similar conditions, tumor-infiltrating T~reg~ were prone to FOXP3 downregulation, attenuation of suppressive function, and prompt IL-17 production ([@B148]). In human lung adenocarcinoma, FOXP3 message amounts correlated with Th17-related transcripts enriched at the tumor site, where IL-17 antagonized the development of the anti-tumor, T-bet-dependent, Th1 response ([@B149]). Myeloid antigen-presenting cells and cytokines such as IL-2, TGF-β, IL-1, IL-23, and IL-6 may initiate T~reg~ polarization into Th17-like cells in these tumor contexts ([@B147]--[@B148][@B149]). In a mouse model of hereditary colon polyposis, as well as in human colon cancer, the Th17-like T~reg~ co-expressed the Th17-related transcription factor ROR-γt, and fostered tumor progression, also through the promotion of mast cell local expansion ([@B150], [@B151]). This study clearly demonstrated that microenvironmental signals could direct T~reg~ plasticity toward pro-inflammatory and pro-tumoral activities.

One group has demonstrated that Th17-like T~reg~ can also arise in experimental tumors as an outcome of vaccination strategies ([@B152]). In this study, vaccination with antigen plus TLR-9 ligand induced T~reg~ reprograming into polyfunctional T-helper-like cells, producing a wide array of cytokines including IL-2, TNF-α, and IL-17, and expressing cell-surface CD40L, thus providing efficient T cell help for tumor-antigen cross-presentation and development of anti-tumor response ([@B152]). The IDO immunosuppressive enzymatic activity was responsible for preventing this anti-tumor T~reg~ polarization, which was instead enhanced using an IDO blocker ([@B152]).

Little data exist on the precursors of Th17-like T~reg~ in cancer. In the peripheral blood of healthy subjects, the CD45RA^−^FOXP3^low^ non-T~reg~ subset was found enriched in Th17-related transcripts and in cells actively secreting IL-17, even at higher levels than naïve or memory T~conv~, a data suggesting that this population contains Th17 or Th17-like precursors ([@B117]). It would be interesting to understand whether the Th17 potential resides, within the non-T~reg~ gate, in activated T~conv~, in latent T~reg~, and/or in recently induced pT~reg~, possibly co-expressing FOXP3 and RORγt and thus pre-committed to the Th17 lineage.

### Th1-like T~reg~ in cancer {#S4-11-8}

Pioneer studies from Koch and colleagues demonstrated that, following exposure to IFN-γ in Th1-dominated microenvironments, a subset of T~reg~ can up-regulate the Th1-related transcription factor T-bet, which drives T~reg~ expansion, migration (CXCR3-mediated), and function specifically during type-1 inflammation ([@B134]). Further experiments have shed light on the developmental requirements and the alternative fates of murine T-bet^+^ T~reg~: following IFN-γ stimulation, T~reg~ could gain T-bet expression but failed to fully polarize into IFN-γ-producing Th1-like T~reg~, due to an impaired T~reg~ susceptibility to IL-12. Indeed, IL-12 receptor β2, which is inducible in T~conv~ in an IFN-γ- and T-bet-dependent fashion, is epigenetically inaccessible in T~reg~ ([@B135]). Only long-lasting IFN-γ preconditioning could unlock IL-12 responsiveness, thus allowing the complete T~reg~ polarization into Th1-like cells ([@B135]). Presumably, in contexts characterized by chronic IFN-γ and IL-12 abundance, such as autoimmune, inflammatory, and viral diseases, T~reg~ will be oriented to a full reprograming into Th1-like cells. Supporting this idea, IFN-γ-producing T~reg~ have been reported in mouse models of graft-versus-host disease ([@B153]), viral ([@B154]) or parasite ([@B142]) infection, in human multiple sclerosis ([@B144]), and diabetes ([@B146], [@B155]). In one of these systems, IFN-γ-producing T~reg~ were recognized to be specific for a foreign (viral) antigen ([@B154]). Whether such Th1-like T~reg~ can be yet considered as classical regulatory cells is still debated. One study has shown that *in vitro* polarized Th1-like T~reg~ were less suppressive than conventional T~reg~ in the standard *in vitro* suppression assay, and that suppression could be partially rescued with concomitant IL-10 and IFN-γ neutralization ([@B144]). Another study has proven that IFN-γ-producing human iT~reg~ were equally functional as natural T~reg~ in suppressing both proliferation and cytokine production of responder T cells ([@B156]). In a mouse model of graft-versus-host disease, IFN-γ produced by stable (TSDR-demethylated) T~reg~ was shown to be even required for T~reg~ protective effect ([@B153]), suggesting that IFN-γ-releasing T~reg~ can display *in vivo* unexpected functions depending on the context.

Conversely, it could be envisaged that, in the tumor context, the low levels of IFN-γ derived from T~conv~, NK, and CD8 cells, and the paucity of IL-12 production by tumor-associated APCs, may concur to induce a pool of T~reg~ expressing T-bet but not secreting IFN-γ, thus specialized in suppressing anti-tumor type-1 immunity. In line with this possibility, TAA-specific T~conv~, but not TAA-specific T~reg~, produced IFN-γ in patients with epithelial ovarian cancer ([@B99]). In both healthy subjects ([@B117]) and malignant melanoma patients ([@B118]), IFN-γ-producing cells were enriched within the circulating CD45RA^−^FOXP3^low^ (CD45RO^+^) non-T~reg~ subset, mostly including activated T~conv~ and/or uncommitted T~reg~. Conversely, in ovarian cancer, tumor-infiltrating T~reg~ were enriched in CXCR3^+^ cells, highly expressing T-bet but poorly producing IFN-γ, and strongly suppressing Th1 response *ex vivo* ([@B157]). Tumor-associated CXCR3^+^ T~reg~ were mostly Helios-positive, and T-bet^+^ T~reg~ could be generated *in vitro* by culturing CD45RA^+^CCR7^+^ rT~reg~ (mostly containing tT~reg~) under Th1-polarizing conditions ([@B157]), suggesting their derivation from committed tT~reg~. This finding was in accordance to Koch et al. who showed that T-bet^+^ T~reg~ derived from T-bet^−^ T~reg~, rather than from activated T~conv~ ([@B134]). These data support the idea that tT~reg~, rather than pT~reg~, may contain the precursors for Th1-specialized suppressors, thus playing critical roles in suppressing protective responses in tumors whose high T~reg~ frequency correlates with poor prognosis ([@B13]).

Some therapeutic interventions can force tumor-associated T~reg~ toward a fully differentiated Th1-like phenotype. For instance, circulating T~reg~ from melanoma patients showed significantly higher IFN-γ secretion following a protocol of tumor peptide vaccination plus IL-2 and cyclophosphamide, in line with enhanced serum IL-12 ([@B158]). On the whole, these data suggest that, especially in the human system, the transition from T-bet^+^ T~reg~, specialized Th1 suppressors, into T-bet^+^ IFN-γ^+^ T~reg~, Th1-like plastic cells, may not only depend on the availability and the responsiveness to exogenous stimuli, but may differentially occur in distinct T~reg~ precursors: on the one side, tT~reg~, enriched in committed and self-specific cells, may be forced to arrest to the specialization (T-bet^+^) endpoint; on the other side, pT~reg~, containing less committed and foreign antigens-specific cells, may be more prone to the complete reprograming into pro-inflammatory (T-bet^+^ IFN-γ^+^) cells. Future studies will elucidate the mechanisms by which different growing tumors may favor the expansion of pro-tumoral specialized Th1 suppressors or the induction of Th1-like plastic T~reg~.

Implications for Cancer Immunotherapy {#S5}
=====================================

The initial enthusiasm on the use of therapeutic cancer vaccines has been soon disappointed by the observation of a low response rate in many trials ([@B159]). After the discovery of T~reg~ as potent immune suppressive cells hampering the establishment of anti-tumor immunity, it soon became clear that anti-tumor vaccination might fail to elicit an effective immune response and to achieve successful tumor eradication, because of the immune suppressive barrier created by T~reg~. In addition, since T~reg~ may recognize TAA and TSA at higher frequency than T~conv~, tumor-antigen-based vaccines may expand/induce T~reg~ rather than effector cells, thus inhibiting rather than boosting the anti-tumor response. Indeed, Zhou et al. first demonstrated that TCR-transgenic CD4 T cells specific for a TAA, adoptively transferred into mice bearing TAA-expressing tumor cells, proliferated extensively after administration of a therapeutic tumor vaccine (in the form of a recombinant vaccinia virus encoding the antigen), but tumor-antigen-experienced cells were mostly regulatory cells, *ex vivo* suppressive, and anergic to subsequent stimulation ([@B81]).

In cancer patients receiving tumor-antigen vaccination, the expansion of antigen-specific T~reg~ has been documented. Circulating NY-ESO-1-specific T~reg~ spontaneously develop in late-stage melanoma patients and are expanded following immunization with NY-ESO-1 protein supplemented with adjuvants ([@B96]). Therapeutic vaccination with an HPV synthetic long peptide vaccine, administered to patients with HPV-positive cervical carcinoma, induced both CD8 and CD4 T cell immunity, but also enhanced the HPV-specific T~reg~ pool ([@B160]). The pool of vaccine-specific T~reg~ may derive not only from the expansion of pre-existing tumor-antigen-specific clones, but also from *de novo* generation of vaccine-specific pT~reg~. This is suggested by results obtained vaccinating melanoma patients with an HLA-DP4-restricted MAGE-A3 peptide: in this setting, a subset of vaccine-specific T~reg~ becomes detectable only after vaccination ([@B161]). Vaccine-elicited T~reg~ showed some degree of heterogeneity: out of five CD25^+^ regulatory clones isolated from vaccinated patients, four expressed high FOXP3 mRNA levels, produced TGF-β, and showed demethylated TSDR; one clone expressed less FOXP3, had methylated TSDR and produced some Th2 cytokines ([@B161]). These data suggest that antigen-specific T~reg~, induced in the periphery following antigen exposure and thus recognizable as pT~reg~, can contain both committed and uncommitted cells.

The concomitant and detrimental T~reg~ expansion in anti-tumor vaccination can be avoided by using CD8 T cell-targeted approaches. A melanoma vaccination protocol based on an MHCI-restricted Melan-A peptide significantly decreased the frequency of Melan-A-specific T~reg~, in association with an improved and more diverse Th1 response ([@B97]).

Some attempts have also been made to combine active immunotherapy with T~reg~ depletion or functional blockade. Several studies showed that depletion of CD25^+^ cells *in vivo* in cancer patients could enhance the tumor-specific T cell responses induced by cancer vaccines ([@B15]). However, CD25-directed strategies may fail to achieve sustained results, since activated effector cells may be concomitantly eliminated and pT~reg~ may replenish the T~reg~ pool after depletion ([@B15]). Interestingly, a recent study has demonstrated that different T~reg~-depleting agents, either CD25-targeted (IL-2/diphtheria toxin fusion protein, or anti-CD25 antibody) or not (low-dose cyclophosphamide), failed to consistently eliminate more than 50% of committed T~reg~, as identified by TSDR demethylation ([@B162]).

Therefore, alternative strategies are needed to counteract the "hard core" of immune suppression that is represented by epigenetically committed T~reg~. We have proposed in the past that T~reg~ functional inactivation, rather than depletion, may represent a successful strategy to prevent massive pT~reg~ induction and concomitantly block T~reg~ suppression ([@B15]). This idea may be corroborated by the observation that markers associated to T~reg~ suppressive functions, and therapeutically targetable, may show enriched or restricted expression in epigenetically committed T~reg~. For instance, GITR stimulation has been shown to attenuate T~reg~ suppression and favor the rejection of experimental tumors ([@B163]). A recent study has demonstrated that GITR engagement *in vivo* led to the downregulation of Foxp3 expression in intratumoral T~reg~ ([@B164]). Of note, GITR^+^ T~reg~ were found enriched in Helios^+^ cells, representing highly committed T~reg~ ([@B131]), thus GITR targeting may preferentially block the strongest suppressors among the T~reg~ pool. A similar possibility could be envisaged for therapeutic strategies aimed at TNF-α/TNFR2 blockade, since this axis may be mainly involved in the activation of more committed and stable cells ([@B122]--[@B123][@B124][@B125][@B126]). Committed T~reg~ may also be targeted by virtue of their high proliferative potential: indeed, high proliferation rates, in terms of Ki67 positivity, were detected in healthy subjects within the aT~reg~ subset, enriched in stable and committed T~reg~ ([@B117]), and also in murine tumor-infiltrating Helios^+^ T~reg~ ([@B131]). Therefore, treatments based on the depletion of proliferating cells, such as low-dose cyclophosphamide, may efficiently target committed T~reg~.

An innovative way to improve immunotherapy would be to reprogram tumor-associated T~reg~ into fully armed effector cells, which would then become "exT~reg~." Different from other vaccine-based approaches, T~reg~ reprograming is expected to trigger anti-tumor response very rapidly, since T~reg~ are already located at the tumor site and already tumor-antigen-experienced, thus not requiring a *de novo* T cell priming. Therefore, exT~reg~ may function in an "innate-like" manner, promptly providing co-stimulatory and pro-inflammatory signals when adequately modulated, before a novel adaptive anti-tumor response develops ([@B140]). An example of this approach has been proposed by Sharma et al. who demonstrated that reprograming of mature pre-existing tumor-associated T~reg~ into CD40L-expressing helper effector cells was needed to achieve tumor regression in a model of immunotherapy combining antigen vaccination, TLR-9 stimulation, and IDO blockade ([@B152]).

The above-discussed data overall indicate that tT~reg~ and pT~reg~ may not be equally susceptible to functional reprograming, but this dichotomy may turn into a benefit for the efficacy and safety of the evoked response. Indeed, on the one hand, tT~reg~, predominantly self-specific, highly committed, and hard to be reprogrammed into T-helper-like cells, would be preserved, thus ensuring immune tolerance to self-antigens and maintaining systemic immune homeostasis. On the other hand, pT~reg~, mainly representing tumor-specific and uncommitted cells, may be more easily converted into exT~reg~, thus mounting an immediate helper and/or effector response in a mostly tumor-antigen-specific fashion.

Reprograming into exT~reg~ may be achieved by immunotherapies aimed at subverting the immune suppression mechanisms established by innate cells in tumor microenvironments. For instance, in the above-reported model of tumor vaccination, CD40L upregulation by T~reg~ following TLR-9 stimulation was strictly dependent on host-derived MyD88 and IL-6 signals ([@B152]). In melanoma patients, tumor peptide antigen vaccination combined with low-dose cyclophosphamide and low-dose IL-2 evoked Th1-like T~reg~ accumulation, in line with a less tolerogenic microenvironment and with enhanced IL-12 availability ([@B158]). Of note, in this system, depletion of proliferating (conceivably committed and thymus-derived) T~reg~ by means of cyclophosphamide allowed the functional reshuffling of innate cells that in turn unveiled the emergence of Th1-like exT~reg~.

However, it is arguable that microenvironmental rearrangements would better accomplish full T~reg~ reprograming with the concomitant direct modulation of T~reg~ activities, aimed especially at enhancing T~reg~ susceptibility to external signals. For instance, expression of IL-12 receptor, which is epigenetically regulated in T~reg~ ([@B135]), could be artificially boosted by pharmacological approaches. Also, targeting with monoclonal antibodies some receptors expressed on T~reg~ surface and correlated with T~reg~ stability (such as TNFR2 and GITR) could result in enhancing T~reg~ propensity to reprograming. In line with this idea, treatment of murine melanomas with a GITR agonistic antibody resulted in the accumulation of exT~reg~ at the tumor site ([@B164]). Suppressor of cytokine signaling (SOCS) 1 and 2, which maintain Foxp3 stability and prevent T~reg~ polarization into effector cells ([@B165], [@B166]), may be pharmacologically inhibited to unlock T~reg~ responsiveness to pro-inflammatory microenvironmental cytokines.

Conclusion {#S6}
==========

Even though discrimination between pT~reg~ and tT~reg~ by simple surface phenotyping is not yet possible many pieces of evidence indicate that both subsets contribute to the T~reg~ pool conditioning the tumor microenvironment. Nevertheless, the development/expansion of pT~reg~ and tT~reg~ are independent processes, possibly resulting from disparate antigens and signals, and their activities seem characterized by very peculiar features in terms of specificity, stability, and specialization. On the one side, tT~reg~ may expand at tumor site in response to self-antigens expressed by tumor cells, mostly include committed (TSDR-demethylated) Helios- and TNFR2-expressing cells, and contain the precursors of specialized T-bet^+^ Th1-suppressing cells, thus representing not only the guardians of systemic immune homeostasis but also the "hard core" of tumor immune escape. On the other side, pT~reg~ may mostly develop following local encounter with TAA or TSA antigens, possibly represent a mixed population of committed (TSDR-demethylated) and uncommitted (TSDR-methylated) cells, and are more prone to be reprogramed into Th1-like or Th17-like effector cells. We envisage that future successful immunotherapies may not only target committed T~reg~ but also favor "recycling" uncommitted T~reg~ into prompt anti-tumor effectors.
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